Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 6 stocks made the list for top value stocks in the Health Care Providers & Services industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.
Why Focus on Undervalued Health Care Providers & Services Stocks?
Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.
AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.
What Goes Into AAII’s Value Grade?
Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.
Click the button below to learn more about A+ Investor and subscribe today.
6 Undervalued Health Care Providers & Services Stocks
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Health Care Providers & Services industry for Thursday, October 10, 2024. Let’s take a closer look at their individual scores to see how they measure up against each other and the Health Care Providers & Services industry median.
| Company | Ticker | Price/Sales | Price/Earnings | EV/EBITDA | Shareholder Yield | Price/Book Value | Price/Free Cash Flow | Value Grade |
| ATI Physical Therapy, Inc. | ATIP | 0.03 | na | 18.9 | (5.4%) | 0.20 | na | B |
| Auna S.A. | AUNA | 0.10 | na | 9.0 | (59.5%) | 0.28 | 0.8 | A |
| Concord Medical Services Holdings Limited | CCM | 0.07 | na | na | 0.2% | 0.02 | na | A |
| Community Health Systems, Inc. | CYH | 0.05 | na | 9.4 | (1.3%) | na | na | B |
| Interpace Biosciences, Inc. | IDXG | 0.21 | 3.0 | 14.7 | (1.5%) | na | 2.9 | A |
| Prenetics Global Limited | PRE | 1.95 | na | 0.6 | (15.3%) | 0.23 | na | B |
The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.
The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)
Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).
As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.
ATI Physical Therapy, Inc.’s Value Grade
Value Grade:
| Metric | Score | ATIP | Industry Median |
| Price/Sales | 1 | 0.03 | 0.94 |
| Price/Earnings | na | na | 24.1 |
| EV/EBITDA | 75 | 18.9 | 14.0 |
| Shareholder Yield | 75 | (5.4%) | (0.8%) |
| Price/Book Value | 5 | 0.20 | 1.94 |
| Price/Free Cash Flow | na | na | 23.2 |
ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work injury rehabilitation services, work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI brand name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
ATI Physical Therapy, Inc. has a Value Score of 66, which is considered to be undervalued.
When you look at ATI Physical Therapy, Inc.’s price-to-sales ratio at 0.03 compared to the industry median at 0.94, this company has a lower price relative to revenue compared to its peers. This could make ATI Physical Therapy, Inc.’s stock more attractive for value investors.
Now, let’s assess ATI Physical Therapy, Inc.’s EV/EBITDA ratio, also known as enterprise multiple. At 18.9, when compared to the industry median of 14.0, the company may be considered overvalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.
Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. ATI Physical Therapy, Inc.’s shareholder yield is lower than its industry median ratio of (0.80%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.
As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. ATI Physical Therapy, Inc.’s price-to-book ratio is lower than its industry median ratio of 1.94. This could make ATI Physical Therapy, Inc. more attractive to investors looking for a new addition to their portfolio.
Auna S.A.’s Value Grade
Value Grade:
| Metric | Score | AUNA | Industry Median |
| Price/Sales | 4 | 0.10 | 0.94 |
| Price/Earnings | na | na | 24.1 |
| EV/EBITDA | 33 | 9.0 | 14.0 |
| Shareholder Yield | 93 | (59.5%) | (0.8%) |
| Price/Book Value | 8 | 0.28 | 1.94 |
| Price/Free Cash Flow | 1 | 0.8 | 23.2 |
Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Auna S.A. has a Value Score of 87, which is considered to be undervalued.
Auna S.A.’s price-to-book ratio is higher than its peers. This could make Auna S.A. less attractive for value investors when compared to the industry median at 1.94.
You can read more about Auna S.A.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Concord Medical Services Holdings Limited’s Value Grade
Value Grade:
| Metric | Score | CCM | Industry Median |
| Price/Sales | 3 | 0.07 | 0.94 |
| Price/Earnings | na | na | 24.1 |
| EV/EBITDA | na | na | 14.0 |
| Shareholder Yield | 43 | 0.2% | (0.8%) |
| Price/Book Value | 0 | 0.02 | 1.94 |
| Price/Free Cash Flow | na | na | 23.2 |
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People’s Republic of China.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Concord Medical Services Holdings Limited has a Value Score of 98, which is considered to be undervalued.
Concord Medical Services Holdings Limited’s price-to-book ratio is higher than its peers. This could make Concord Medical Services Holdings Limited less attractive for value investors when compared to the industry median at 1.94.
You can read more about Concord Medical Services Holdings Limited’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Community Health Systems, Inc.’s Value Grade
Value Grade:
| Metric | Score | CYH | Industry Median |
| Price/Sales | 2 | 0.05 | 0.94 |
| Price/Earnings | na | na | 24.1 |
| EV/EBITDA | 36 | 9.4 | 14.0 |
| Shareholder Yield | 62 | (1.3%) | (0.8%) |
| Price/Book Value | na | na | 1.94 |
| Price/Free Cash Flow | na | na | 23.2 |
Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. The company was incorporated in 1996 and is headquartered in Franklin, Tennessee.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Community Health Systems, Inc. has a Value Score of 78, which is considered to be undervalued.
You can read more about Community Health Systems, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Interpace Biosciences, Inc.’s Value Grade
Value Grade:
| Metric | Score | IDXG | Industry Median |
| Price/Sales | 9 | 0.21 | 0.94 |
| Price/Earnings | 2 | 3.0 | 24.1 |
| EV/EBITDA | 61 | 14.7 | 14.0 |
| Shareholder Yield | 63 | (1.5%) | (0.8%) |
| Price/Book Value | na | na | 1.94 |
| Price/Free Cash Flow | 6 | 2.9 | 23.2 |
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Interpace Biosciences, Inc. has a Value Score of 87, which is considered to be undervalued.
Interpace Biosciences, Inc.’s price-earnings ratio is 3.0 compared to the industry median at 24.1. This means that it has a lower price relative to its earnings compared to its peers. This makes Interpace Biosciences, Inc. more attractive for value investors.
You can read more about Interpace Biosciences, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Prenetics Global Limited’s Value Grade
Value Grade:
| Metric | Score | PRE | Industry Median |
| Price/Sales | 51 | 1.95 | 0.94 |
| Price/Earnings | na | na | 24.1 |
| EV/EBITDA | 2 | 0.6 | 14.0 |
| Shareholder Yield | 82 | (15.3%) | (0.8%) |
| Price/Book Value | 6 | 0.23 | 1.94 |
| Price/Free Cash Flow | na | na | 23.2 |
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company’s consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes Insighta, a multi-cancer early detection technology. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. It operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Prenetics Global Limited has a Value Score of 73, which is considered to be undervalued.
Prenetics Global Limited’s price-to-book ratio is higher than its peers. This could make Prenetics Global Limited less attractive for value investors when compared to the industry median at 1.94.
You can read more about Prenetics Global Limited’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Other Health Care Providers & Services Stock Grades
Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.
Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Health Care Providers & Services stocks as well as other industrys.
Choosing Which of the 6 Best Health Care Providers & Services Stocks Is Right for You
Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.
- ATI Physical Therapy, Inc. stock has a Value Grade of B.
- Auna S.A. stock has a Value Grade of A.
- Concord Medical Services Holdings Limited stock has a Value Grade of A.
- Community Health Systems, Inc. stock has a Value Grade of B.
- Interpace Biosciences, Inc. stock has a Value Grade of A.
- Prenetics Global Limited stock has a Value Grade of B.
Now that you have a bit more background about each of the 6 undervalued stocks in the Health Care Providers & Services industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.
We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.
A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
Additional Resources About Health Care Providers & Services Stocks
Want to learn more about Health Care Providers & Services stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.
- 6 Undervalued Health Care Providers & Services Stocks for Thursday, October 10
- 3 Undervalued Health Care Providers & Services Stocks for Wednesday, October 09
- 4 Undervalued Health Care Providers & Services Stocks for Tuesday, October 08
- 5 Undervalued Health Care Providers & Services Stocks for Monday, October 07
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.
Included With AAII Platinum
Screen: 23.7%
Annual Gain Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.